Violetta Cotreau - 12 May 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Accounting Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Violetta Cotreau
Issuer symbol
AKBA
Transactions as of
12 May 2022
Net transactions value
$0
Form type
4
Filing time
16 May 2022, 16:04:38 UTC
Previous filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +150,000 +214% $0.000000 219,954 12 May 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date.